Stephens Inc. AR Reduces Holdings in Humana Inc. (NYSE:HUM)

Stephens Inc. AR decreased its position in Humana Inc. (NYSE:HUM) by 32.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,355 shares of the insurance provider’s stock after selling 641 shares during the period. Stephens Inc. AR’s holdings in Humana were worth $344,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Creative Financial Designs Inc. ADV lifted its holdings in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the period. Ashton Thomas Securities LLC acquired a new position in shares of Humana during the third quarter valued at approximately $31,000. Your Advocates Ltd. LLP lifted its holdings in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. Atwood & Palmer Inc. lifted its stake in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares in the last quarter. Finally, LRI Investments LLC boosted its holdings in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after purchasing an additional 143 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HUM. Wells Fargo & Company dropped their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and raised their target price for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price target on shares of Humana in a report on Wednesday. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $293.05.

Humana Stock Performance

Shares of HUM opened at $253.61 on Friday. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The stock has a market capitalization of $30.54 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company’s fifty day moving average is $271.27 and its two-hundred day moving average is $294.21.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, sell-side analysts predict that Humana Inc. will post 16.11 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.32% of the stock is currently owned by corporate insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.